Similar personal injury attorneys in Philadelphia
Prior results do not guarantee a similar outcome. Each case is unique and depends on its own facts.
About Thomas Anapol
Tom Anapol is the Director and Managing Shareholder of Anapol Weiss. He joined the firm as an Associate in 1991, in or about when his father retired. Tom became non-equity partner in 1998 and an equity partner in 2003. He has been the firm's Managing Shareholder since 2019 and is now its director.
Mass tort litigation has been Tom's main practice area throughout his career. He has served in various coordinated leadership capacities in state and multidistrict (MDL) medical device litigations including multiple heart device, metal-on-metal hip and transvaginal mesh litigations. As Managing Shareholder, he has led the firm through a transformation from a traditional personal injury and mass torts firm to one that is majority-owned by female attorneys. As of September of 2024, more than half of the firm's shareholders and partners are women.
The firm concurrently expanded its historical mass tort medical device and drug litigation practice and now focuses upon representing victims of institutional sex abuse practices. Leadership in the legal industry has been a constant in Tom's career. He has served on the Board of Governors for the Pennsylvania Association for Justice (PAJ) for over 25 years culminating in his service as President in 2016. Tom also served for many years on the Board of Governors for the American Association for Justice (AAJ).
Proven verdicts and settlements
On Nov. 3, 2014, Howmedica Osteonics, doing business as Stryker Orthopaedics, settled the claims of about 3,000 people who had surgery to remove recalled Rejuvenate and ABG II modular hip stems. The deal was announced in the Bergen County courthouse and paired with a parallel proceeding in the federal MDL in Minnesota. It sets a base award per failed implant plus enhancements for complications, with no fixed fund, and was expected to pay out more than $1 billion. Thomas Anapol of Anapol Schwartz sat on the court-appointed Plaintiff Steering Committee for the New Jersey litigation.
In early 2014, Biomet agreed to pay at least $56 million to settle about 1,000 federal lawsuits over its M2a 38 and M2a Magnum metal-on-metal hip implants, consolidated in the Northern District of Indiana. Qualifying patients who had the device revised received a base award of $200,000, adjusted by individual factors. Thomas Anapol was court-appointed Co-Lead Counsel with W. Mark Lanier and signed the agreement for the Plaintiffs' Executive Committee. The figure covers many unrelated plaintiffs, is a reported minimum rather than a final total, and is not itemized by person.
Prior results do not guarantee a similar outcome. Each case is unique and depends on its own facts.
Practice areas
Education
Other attorneys at Anapol Weiss
View firm →
Proven verdicts and settlements from other Philadelphia firms
Prior results do not guarantee a similar outcome. Each case is unique and depends on its own facts.